Here are the 10-K annual reports from LB Pharmaceuticals Inc (LBRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LBRX filings page.
LB Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on neuropsychiatric disorders, built around its lead candidate LB-102, a novel, methylated benzamide antipsychotic. LB-102 is designed to improve on amisulpride by enhancing blood–brain barrier penetration, enabling lower, once-daily dosing while preserving a selective D2/D3/5-HT7 receptor profile.
The company reported positive results from a four-week Phase 2 trial in acute schizophrenia, where LB-102 achieved statistically significant reductions in PANSS total scores across 50 mg, 75 mg, and 100 mg doses, with responder rates up to 78.3% and a tolerability profile characterized by low rates of EPS (including akathisia), minimal sedation, and few gastrointestinal effects. Exploratory analyses suggested benefits on negative symptoms and cognition using the CogState battery, with effect sizes increasing by dose and mediation analyses indicating a primarily direct cognitive effect.
LB Pharmaceuticals has initiated a six-week Phase 3 schizophrenia trial (NOVA-2) in the United States comparing 50 mg and 100 mg LB-102 versus placebo, targeting approximately 460 patients, and expects topline data in the second half of 2027. It is also running or planning Phase 2 programs in bipolar 1 depression (ILLUMINATE-1, topline data expected in the first quarter of 2028) and adjunctive major depressive disorder, and is developing a long-acting injectable formulation to address adherence. The company holds global rights to LB-102 and intends to retain U.S. commercialization while evaluating ex-U.S. collaborations.